COMPUGEN LTD (CGEN) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: August 22, 2025
COMPUGEN LTD (CGEN) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
COMPUGEN LTD (Stock Symbol: CGEN)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $136 million - Classified as a
small-cap investment offering high growth potential.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for COMPUGEN LTD stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
COMPUGEN LTD strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
COMPUGEN LTD Stock Price Chart and Technical Analysis
Loading chart data...
Loading COMPUGEN LTD interactive price chart and technical analysis...
Deep dive into COMPUGEN LTD's financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if COMPUGEN LTD stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For COMPUGEN LTD:
P/B Ratio2.70x
Market Cap$136M
Book Value/Share$0.54
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently COMPUGEN LTD converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For COMPUGEN LTD:
Understanding Financial Health Metrics
What these metrics mean: These ratios assess COMPUGEN LTD's ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For COMPUGEN LTD:
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal COMPUGEN LTD's ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For COMPUGEN LTD:
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively COMPUGEN LTD uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For COMPUGEN LTD:
Understanding Financial Statement Data
What these metrics mean: Key figures from COMPUGEN LTD's income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For COMPUGEN LTD:
Income Statement ($ Millions)
Balance Sheet Highlights ($ Millions)
Dividend & Shareholder Information
Shares Outstanding94M
COMPUGEN LTD (CGEN) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for COMPUGEN LTD stock analysis.
Loading fundamental data...
Loading COMPUGEN LTD comprehensive fundamental analysis and insider trading data...
Latest COMPUGEN LTD Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting COMPUGEN LTD (CGEN) stock price and investment outlook.
Today is shaping up negative for Compugen Ltd. (NASDAQ:CGEN) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. Both revenue and earnings per ...
Compugen (NASDAQ:CGEN) has had a rough three months with its share price down 19%. But if you pay close attention, you might find that its key financial indicators look quite decent, which could ...
Compugen Ltd has a consensus price target of $5.42 based on the ratings of 6 analysts. The high is $13 issued by EF Hutton on August 7, 2023. The low is $0.5 issued by Jefferies on February 8, 2023.
HOLON, Israel, July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target ...
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Dr. Roy Granit, Head of Computational ...
HOLON, ISRAEL, May 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...
HOLON, Israel, Feb. 20, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced its plan to ...
Company Profile Compugen Ltd. Azrieli Center 26 Harokmim Street Building D Holon, TA 58858 Phone972 3 765-8585 IndustryPharmaceuticals SectorHealth Care/Life Sciences Fiscal Year-end12/2025 ...
Investors are always looking for stocks that are poised to beat at earnings season and Compugen Ltd. CGEN may be one such company. The firm has earnings coming up pretty soon, and events are ...
HOLON, Israel, July 19, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first ...
GENEVA-- (BUSINESS WIRE)-- Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today that Compugen Ltd. has taken a license ...
COMPUGEN LTD Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of COMPUGEN LTD against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Our AI model demonstrates 23% historical accuracy for CGEN predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence COMPUGEN LTD stock price forecasts?
Based on our AI analysis, COMPUGEN LTD shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are COMPUGEN LTD forecasts updated?
COMPUGEN LTD stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced COMPUGEN LTD Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for COMPUGEN LTD stock.
